GuidelineThe Lancet. Child & adolescent health2020
Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline.
Guideline in The Lancet. Child & adolescent health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 117 citations in OpenAlex.
- Otoprotective Effects of Sodium Thiosulfate by Demographic and Clinical Characteristics: A Report From Children's Oncology Group Study ACCL0431.Pediatric blood & cancer · 2025Trial
- Advances in the clinical applications of sodium thiosulphate.Annals of medicine · 2026Review
- Paeonol Alleviate Cisplatin- and Noise-Induced Hearing Loss by Preserving Hair Cell Ribosome Biogenesis.CNS neuroscience & therapeutics · 2026Article
- Cycloastragenol Protects Against Cisplatin-Induced Cochlear Hair Cell Apoptosis via the PI3K/Akt/mTOR Pathway.Cellular and molecular neurobiology · 2026Article
- Review
- Cancer therapy-induced ototoxicity: Current challenges and emerging management strategies.Animal models and experimental medicine · 2026Review
- Therapeutic Potential of MgHNeuroscience bulletin · 2026Article
- Efficacy and mechanisms of cisplatin and sulforaphane nanoparticles in alleviating cisplatin resistance in non-small cell lung cancer.Translational lung cancer research · 2026Article
- Dinaciclib improves treatment response in chemoresistant hepatoblastoma.Scientific reports · 2025Article
- Polyphenolic compounds as protective agents against cisplatin-induced ototoxicity with molecular mechanisms and clinical potential.RSC medicinal chemistry · 2025Review
- Transtympanic Injection of Antioxidant-Eluting Microparticles for Otoprotection From Cisplatin Toxicity in a Mouse Model.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2025Article
- [Preliminary efficacy and safety of a dose-intensified C5VD regimen in 24 children with locally advanced hepatoblastoma].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Article
- Critical Review of Hearing Rehabilitation in Pediatric Oncology: Specific Considerations and Barriers.Current oncology (Toronto, Ont.) · 2025Review
- Inhibition of inner ear macrophage phagocytosis alleviates cisplatin-induced ototoxicity.Communications biology · 2025Article
- The prognostic value of baseline EARL standardized FDG PET indices in pediatric and adolescent high-grade osteosarcoma.European radiology · 2025Article
- Cisplatin-Induced APE2 Overexpression Disrupts MYH9 Function and Causes Hearing Loss.Cancer research communications · 2025Article
- Ferulic Acid Combines with Ascorbic Acid to Target MMP9 to Attenuate Cisplatin-Induced Ototoxicity Through the p38MAPK Signaling Pathway.Antioxidants (Basel, Switzerland) · 2025Article
- Approaches to Reduce Toxicity in Pediatric Brain Tumors.Current oncology (Toronto, Ont.) · 2025Review
- SIRT3 regulates PFKFB3-mediated glycolysis to attenuate cisplatin-induced ototoxicity both in vivo and in vitro.Archives of toxicology · 2025Article
- Assessment and Management of Chemotherapy-Induced Ototoxicity in Children.Journal of audiology & otology · 2025Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 11 institutions in 5 countries.
Funding
Abstract
Despite ototoxicity being a prevalent consequence of cisplatin chemotherapy, little guidance exists on interventions to prevent this permanent and progressive adverse event. To develop a clinical practice guideline for the prevention of cisplatin-induced ototoxicity in children and adolescents with cancer, we convened an international, multidisciplinary panel of experts and patient advocates to update a systematic review of randomised trials for the prevention of cisplatin-induced ototoxicity. The systematic review identified 27 eligible adult and paediatric trials that evaluated amifostine, sodium diethyldithiocarbamate or disulfiram, systemic sodium thiosulfate, intratympanic therapies, and cisplatin infusion duration. Regarding systemic sodium thiosulfate, the panel made a strong recommendation for administration in non-metastatic hepatoblastoma, a weak recommendation for administration in other non-metastatic cancers, and a weak recommendation against its routine use in metastatic cancers. Amifostine, sodium diethyldithiocarbamate, and intratympanic therapy should not be routinely used. Cisplatin infusion duration should not be altered as a means to reduce ototoxicity. Further research to determine the safety of sodium thiosulfate in patients with metastatic cancer is encouraged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.